Nanomedicine embraces cancer radio-immunotherapy: mechanism, design, recent advances, and clinical translation

Chemical Society Reviews, Journal Year: 2022, Volume and Issue: 52(1), P. 47 - 96

Published: Nov. 25, 2022

This review overviews the landscape of nanomedicine-aided cancer radio-immunotherapy in a “from bench to clinic” manner.

Language: Английский

---

Synthesis of thieno[3,2-e]pyrrolo[1,2-a]pyrimidine derivatives and their precursors containing 2-aminothiophenes fragments as anticancer agents for therapy of pulmonary metastatic melanoma

European Journal of Medicinal Chemistry, Journal Year: 2023, Volume and Issue: 254, P. 115325 - 115325

Published: April 13, 2023

Language: Английский

---

Development of Nanocarrier-Based Radionuclide and Photothermal Therapy in Combination with Chemotherapy in Melanoma Cancer Treatment

ACS Applied Materials & Interfaces, Journal Year: 2023, Volume and Issue: 15(10), P. 13460 - 13471

Published: March 3, 2023

Conventional cancer therapy methods have serious drawbacks that are related to the nonspecific action of anticancer drugs leads high toxicity on normal cells and increases risk recurrence. The therapeutic effect can be significantly enhanced when various treatment modalities implemented. Here, we demonstrate radio- photothermal (PTT) delivered through nanocarriers (gold nanorods, Au NRs) in combination with chemotherapy a melanoma results complete tumor inhibition compared single therapy. synthesized effectively labeled 188Re radionuclide radiolabeling efficiency (94-98%) radiochemical stability (>95%) appropriate for Further, 188Re-Au NRs, mediating conversion laser radiation into heat, were intratumorally injected PTT was applied. Upon irradiation near-infrared laser, dual achieved. Additionally, 188Re-labeled NRs paclitaxel (PTX) has improved (188Re-labeled irradiation, PTX) monoregime. Thus, this local triple-combination step toward clinical translation use treatment.

Language: Английский

---

The Dual Role of the Innate Immune System in the Effectiveness of mRNA Therapeutics

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(19), P. 14820 - 14820

Published: Oct. 1, 2023

Advances in molecular biology have revolutionized the use of messenger RNA (mRNA) as a therapeutic. The concept nucleic acid therapy with mRNA originated 1990 when Wolff et al. reported successful expression proteins target organs by direct injection either plasmid DNA or mRNA. It took decades to bring transfection efficiency closer that DNA. next few were dedicated turning vitro-transcribed (IVT) from promising delivery tool for gene into full-blown therapeutic modality, which changed biotech market rapidly. Hundreds clinical trials are currently underway using prophylaxis and infectious diseases cancers, regenerative medicine, genome editing. potential IVT induce an innate immune response favors its vaccination immunotherapy. Nonetheless, non-immunotherapy applications, intrinsic immunostimulatory activity directly hinders desired effect since it can seriously impair protein expression. Targeting same factors increase effectiveness therapeutics some indications decrease others, vice versa. review aims present immunity-related ‘barriers’ ‘springboards’ may affect development immunotherapies applications medicines.

Language: Английский

---

Development of novel radiolabeled antibody-conjugated graphene quantum dots for targeted in vivo breast cancer imaging and biodistribution studies

Arabian Journal of Chemistry, Journal Year: 2023, Volume and Issue: 17(2), P. 105518 - 105518

Published: Dec. 4, 2023

Nanotechnology-based drug delivery platforms have emerged as one of the promising approaches for diagnosis and treatment cancers. Furthermore, significant advancements been achieved in development nanoparticle-antibody conjugates applications tumor imaging immunoassays. Without a doubt, diagnostic insight garnered from these nanoprobes will prove invaluable determining rational therapeutic strategies. In current experiment, we developed breast cancer probe utilizing graphene quantum dots, dots were conjugated with pembrolizumab (GQDs–pembrolizumab), human monoclonal antibody (mAb) targeting immune checkpoint programmed death receptor (PD-1) its ligand-1 (PD-L1). Various techniques employed characterization, encompassing transmission electron microscopy (TEM), element mapping, atomic force (AFM), Fourier-transform infrared spectroscopy, circular dichroism (CD) spectroscopy. The toxicity nanoconjugate was evaluated using MTT assay on HEK-293 4T1 cell lines. Subsequently, synthesized radiolabeled Technetium-99m (99mTc) to produce 99mTc-GQDs–pembrolizumab. Biodistribution SPECT conducted assess pharmacokinetics efficacy 99mTc-GQDs–pembrolizumab BALB/c mouse model bearing tumors. high Radiochemical purity (RCP>95%) satisfactory vitro stability demonstrate potential GQDs–pembrolizumab form complexes Technetium-99m. findings biodistribution studies demonstrated activity at site (8.4 %ID/g), attributed presence PD-1 receptor. increased radiotracer uptake evident liver spleen, both being lymphoid tissues. suitable properties behavior suggest that it holds promise novel radiopharmaceutical-based antibodies. Additionally, has facilitate immunotherapy treating wide range

Language: Английский

---

Encapsulation of a small-molecule drug based on substituted 2-aminothiophenes in calcium carbonate carriers for therapy of melanoma

Biomaterials Science, Journal Year: 2024, Volume and Issue: 12(13), P. 3431 - 3445

Published: Jan. 1, 2024

Encapsulation of 2-aminothiophenes in calcium carbonate particles leads to improved antitumor activity against melanoma.

Language: Английский

---

Calcium carbonate nanoparticles tumor delivery for combined chemo-photodynamic therapy: Comparison of local and systemic administration

Journal of Controlled Release, Journal Year: 2023, Volume and Issue: 359, P. 400 - 414

Published: June 16, 2023

Language: Английский

---

Macrocyclic-Albumin Conjugates for Precise Delivery of Radionuclides and Anticancer Drugs to Tumors

ACS Nano, Journal Year: 2023, Volume and Issue: 17(22), P. 22399 - 22409

Published: Nov. 6, 2023

Precise delivery of radionuclides and anticancer drugs to tumor tissue is crucial ensuring drug synergism optimal therapeutic effects in radionuclide-based combination radio-chemotherapy. However, current codelivery vectors often rely on physical embedment/adsorption load drugs, which lacks precise mechanisms for loading release, resulting unpredictable effects. Herein, a macrocyclic-albumin conjugate (MAC) that enables controlled release presented. By conjugating multiple macrocyclic hosts (sulfonate azocalix[4]arenes, SAC4A) albumin molecules, the MAC facilitates through host-guest interactions site-specific labeling radionuclides. Furthermore, degrades under hypoxic conditions, enabling loaded upon reaching tissues. Through targeted achieves efficient cancer diagnosis combined radio-chemotherapy breast cell (4T1)-bearing mice. Considering SAC4A can many may provide promising platform effective

Language: Английский

---

Comparison of passive targeted delivery of inorganic and organic nanocarriers among different types of tumors

Nanomedicine Nanotechnology Biology and Medicine, Journal Year: 2024, Volume and Issue: 59, P. 102753 - 102753

Published: May 9, 2024

Language: Английский

---

Radionuclide labeled nanocarrier for imaging guided combined radionuclide, sonodynamic, and photothermal therapy of pancreatic tumours

Journal of Colloid and Interface Science, Journal Year: 2023, Volume and Issue: 642, P. 789 - 799

Published: March 30, 2023

Language: Английский

---